
    
      The AIDA trial is a prospective, randomized (1:1), active control, single blinded,
      four-center, all-comers, non-inferiority trial. A total of 1845 patients were enrolled. The
      study population includes both simple and complex lesions, as well as stable and acute
      coronary syndrome patients. The follow-up will continue for 5 years including clinical
      endpoint characteristics.
    
  